00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
19:25 , Oct 5, 2018 |  BC Week In Review  |  Company News

Deal adds HBV therapy to Janssen pipeline, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
11:31 , Oct 4, 2018 |  BC Extra  |  Company News

Deal satisfies Janssen HBV strategy, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection....
20:42 , Sep 6, 2018 |  BC Extra  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of...
16:26 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Arrowhead raises $60.4M follow-on

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) raised $60.4 million through the sale of 11.5 million shares at $5.25 in a follow-on, including a 1.5 million share overallotment, on Jan. 22. Jefferies, Barclays Capital, Cantor Fitzgerald, Chardan...
22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
22:34 , Sep 28, 2017 |  BC Extra  |  Preclinical News

Arrowhead paper reveals additional HBV antigen source

A paper published in...